Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SGB 3383

Next Previous
Drug Profile

SGB 3383

Alternative Names: SGB-3383

Latest Information Update: 04 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SanegeneBio
  • Class Small interfering RNA
  • Mechanism of Action Complement factor B expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haemolytic uraemic syndrome; IgA nephropathy; Membranoproliferative glomerulonephritis

Most Recent Events

  • 04 Jun 2025 SGB 3383 is available for licensing as of 04 Jun 2025. https://www.sanegenebio.com/
  • 03 Jun 2025 SanegeneBio plans a phase I trial (In volunteers) (SC, Injection) in June 2025 (NCT06995326)
  • 20 May 2025 Preclinical trials in Haemolytic uraemic syndrome in USA (SC) before May 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top